Helicobacter Pylori Test Market

The growing prevalence of infectious diseases is driving the market growth

Market CAGR for H. Pylori (Helicobacter Pylori) Test is being driven by the rising spread of infectious diseases. The prime factors expediting the market’s growth are the increased prevalence of infectious diseases and people's growing knowledge of infections. The most prevalent infectious disorders brought on by bacteria are gonorrhoea, chlamydia, tuberculosis, various STDs, gastroenteritis, and urinary tract infections (UTIs). For instance, the prevalence of peptic ulcers worldwide in 2021 was approximately 8.4%, according to a study with the title "The Prevalence of Peptic Ulcer in the World: a Systematic Review and Meta-analysis" that was published in December 2021.

Similar to this, according to a report released by Medscape in April 2021, 4.6 million Americans experience peptic ulcer illness each year. Similar to this, the European Centre for Disease Prevention and Control announced in March 2021 that the European Union, European Economic Area (EEA), and the United Kingdom each identify about 500,000 new cases of sexually transmitted illnesses annually. Instances like these illustrate that the market is anticipated to experience significant expansion over the projected period because helicobacter pylori diagnostics are typically advised for the diagnosis of infectious disorders.

A gram-negative aerobic bacteria commonly found in the stomach is called Helicobacter pylori (H. pylori). While it maintains the ecology of the stomach, it can also infect the inner stomach lining. Infection in the small intestine, gastritis, duodenal ulcers, stomach cancer, and gastric ulcers can all be brought on by the bacterium. This has enhanced the need for H. pylori infection diagnosis tools. In the event that Helicobacter pylori-related ulcers are confirmed, patients must undergo antibiotic therapy for 10 to 14 days.

Short treatment periods and easy access to antibiotics will further increase the demand for pre- and post-monitoring testing as well as the usage of antibiotics. In addition, increasing H. pylori infections, the necessity for early symptom detection, and technical developments in diagnostic methods are some of the reasons propelling the market's expansion. Thus, driving the Helicobacter Pylori (H. Pylori) Test Market revenue.

The Global Helicobacter Pylori Test Market Industry is projected to experience substantial growth over the next decade. With a market value of 3.23 USD Billion in 2024, it is anticipated to reach 5.95 USD Billion by 2035, reflecting a robust CAGR of 5.71% from 2025 to 2035. This growth trajectory indicates a rising demand for effective diagnostic solutions and highlights the increasing recognition of Helicobacter Pylori as a critical public health concern. The market's expansion is likely to be fueled by advancements in testing technologies, heightened awareness, and supportive regulatory frameworks.

Support from regulatory bodies and the establishment of clinical guidelines for Helicobacter Pylori testing bolster the Global Helicobacter Pylori Test Market Industry. Organizations such as the World Health Organization advocate for the testing and treatment of Helicobacter Pylori infections, influencing healthcare policies worldwide. This regulatory backing encourages healthcare providers to adopt testing protocols, thereby increasing market penetration. As guidelines evolve and emphasize the importance of early detection, the market is expected to experience sustained growth, driven by compliance with these recommendations.

The rising prevalence of gastrointestinal disorders, such as gastritis and peptic ulcers, is a significant driver for the Global Helicobacter Pylori Test Market Industry. These conditions are often associated with Helicobacter Pylori infections, prompting healthcare professionals to recommend testing as a standard diagnostic procedure. As more individuals seek medical attention for gastrointestinal symptoms, the demand for reliable testing methods is expected to rise. This trend is likely to contribute to the market's growth, as healthcare systems prioritize effective diagnosis and management of these disorders.

Technological innovations in diagnostic methods are enhancing the accuracy and efficiency of Helicobacter Pylori testing. The Global Helicobacter Pylori Test Market Industry benefits from the introduction of non-invasive tests, such as breath tests and stool antigen tests, which are gaining traction among healthcare professionals. These advancements not only improve patient compliance but also reduce the burden on healthcare systems. As the market evolves, it is expected to grow at a CAGR of 5.71% from 2025 to 2035, potentially reaching 5.95 USD Billion by 2035, reflecting the increasing reliance on advanced diagnostic technologies.

Public health campaigns aimed at raising awareness about Helicobacter Pylori infections are crucial in driving the Global Helicobacter Pylori Test Market Industry. Educational initiatives by health organizations emphasize the importance of early detection and treatment of infections to prevent complications such as peptic ulcers and gastric cancer. This heightened awareness leads to increased testing and diagnosis rates, thereby expanding the market. As healthcare providers and patients become more informed about the risks associated with Helicobacter Pylori, the demand for testing solutions is likely to surge.

The increasing incidence of Helicobacter Pylori infections globally drives the demand for testing solutions. According to health statistics, approximately 50% of the world's population is estimated to be infected with this bacterium, which is linked to various gastrointestinal disorders. The Global Helicobacter Pylori Test Market Industry is poised to grow significantly as awareness of these infections rises. With the market projected to reach 3.23 USD Billion in 2024, healthcare providers are increasingly adopting diagnostic tests to manage and treat affected individuals effectively.

 By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Helicobacter Pylori (H. Pylori) Test Market area will dominate this market, owing to presence and consistent development of healthcare infrastructure and better economy.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: H. PYLORI (HELICOBACTER PYLORI) TEST MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe Helicobacter Pylori (H. Pylori) Test Market accounted for the second-biggest market share due to the increasing count of infectious diseases and rising awareness for diagnostics. Further, the German Helicobacter Pylori (H. Pylori) Test Market held the biggest market share, and the UK Helicobacter Pylori (H. Pylori) Test Market was the fastest-growing market in the European region

The Asia-Pacific Helicobacter Pylori (H. Pylori) Test Market is expected to grow at the fastest CAGR. This is due to growing cases of H. Pylori disease and growing populations Moreover, China’s Helicobacter Pylori (H. Pylori) Test Market held the biggest market share, and the Indian Helicobacter Pylori (H. Pylori) Test Market was the fastest growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Helicobacter Pylori (H. Pylori) Test Market, grow even more. Market players are also adopting a variety of strategies to extend their presence, with important market developments including new product innovations, contracts & agreements, mergers &s acquisitions, higher investments, and collaboration with other similar organizations. To expand and survive in a more competitive and rising market climate, the H. Pylori (Helicobacter Pylori) Test industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the H. Pylori (Helicobacter Pylori) Test industry to benefit clients and increase the market sector. In recent years, the H. Pylori (Helicobacter Pylori) Test industry has offered some of the most significant advantages to medicine. Major players in the Helicobacter Pylori (H.

Pylori) Test Market, including Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), Hoffmann-La Roche Ltd (Switzerland), Quest Diagnostics Incorporated (US), Meridian Bioscience (US), CorisBioconcept SPRL (Belgium), Cardinal Health (US), QIAGEN (Germany), Abbott Laboratories (US), and Biohit Oyj (Finland), and others, are attempting to increase market demand by investing in research and development operations.

The company Biomerica Inc. (Biomerica) creates, produces, and sells medical diagnostic tools for the early identification and follow-up of chronic illnesses and medical problems. Diagnostic test kits from the company are used to examine patient blood, urine, and faecal materials in order to identify various illnesses and medical issues. By utilising enzyme immunoassay technology, it focuses on the development of products for diabetes, gastrointestinal, food intolerances, and esoteric diagnostics. Worldwide, consumers, clinical laboratories, hospitals, and doctor's offices employ the diagnostic tests produced by Biomerica.

In May 2022, Helicobacter pylori bacteria are found using the hp+detect diagnostic test from Biomerica, Inc., which just received the CE Mark. After the device has been registered in each country where it will be sold, the corporation will start marketing and selling its hp+detect diagnostic test there and in other nations.

A fully integrated life science company, Meridian Bioscience Inc. (Meridian) creates, produces, and sells diagnostic test kits for the detection of infectious diseases caused by viruses, gastrointestinal disorders, respiratory disorders, and parasites. For use in research and the production of diagnostics, the company also produces bulk antigens, antibodies, purified reagents, nucleotides, and related goods. It creates proteins and other biological components for use in biotechnology studies of novel medications and vaccines. Meridian offers its products to acute care hospitals, outpatient clinics, reference laboratories and physician office laboratories in several countries worldwide.

In July 2023, Otsuka America Pharmaceutical, Inc.'s North American BreathTek business will be acquired by Meridian Bioscience, Inc. for $20 million in cash, according to a definitive deal signed by the two parties today. Meridian Bioscience, Inc. is a top producer of testing solutions for diagnosis and life science raw materials globally. The deal is anticipated to be finalize in Meridian's fourth fiscal quarter.